Exposure-response relationship of nivolumab and ipilimumab in patients with metastatic renal cell carcinoma from the randomised phase 2 BIONIKK study

Puntos clave

• Exposure-response relationship was observed between nivolumab and ipilimumab treatment and patient outcomes.
• Nivolumab combined with ipilimumab led to improved overall survival in metastatic renal cell carcinoma patients.
• Analysis conducted in a randomised phase 2 study setting across multiple treatment centers.
• Findings highlight the importance of individualized dosing strategies for better outcomes based on biomarker responses.